In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections

Clinical Infectious Diseases

Volumn 41, Issue 5 SUPPL., 2005, Pages

  Bradford, Patricia A ^a   Weaver Sands, D Tasha ^a   Petersen, Peter J ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFTAZIDIME; IMIPENEM; LEVOFLOXACIN; MINOCYCLINE; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ABDOMINAL INFECTION; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; CLINICAL TRIAL; ESCHERICHIA COLI; GEOGRAPHY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEACEAE; PSEUDOMONAS AERUGINOSA; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS, PHASE III; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INTESTINAL DISEASES; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SKIN DISEASES, BACTERIAL;

EID: 23844542728     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/431673     Document Type: Article

References (28)

1. Sum PE, Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett 1999; 9:1459-62.
2. Bauer G, Berens C, Projan SJ, Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004; 53:592-9.
3. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antimicrobial activities of a novel glycylcycline, the 9-t-butyl-glycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43:738-44.
4. Bradford PA. Tigecycline: a first in class glycylcycline. Clin Microbiol Newslett 2004; 26:163-8.
5. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001; 45:2604-8.
6. Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents 2000; 16:61-3.
7. Wallace RJ Jr, Brown-Elliot BA, Crist CJ, Wallace RJ. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46:3164-7.
8. Breedt J, Teras J, Gardovskis J, et al. The safety and efficacy of tigecycline in the treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin/aztreonam. Antimicrob Agents Chemother (in press).
9. Fomin P, Beuran M, Gradauskas A, et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg (in press).
10. Rose G, Loh E. Efficacy and safety of tigecycline compared with vancomycin/aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial [control no. TH-13]. In: Program and abstracts of the 11th Annual International Symposium on Staphylococci and Staphylococcal Infections (Charleston, SC). International Society on Staphylococci and Staphylococcal Infections, 2004.
11. Ellis-Grosse EJ, Loh E. Tigecycline compared with imipenem/cilastatin in the treatment of complicated intra-abdominal infections [poster P1317], In: Program and abstracts of the 15th European Congress of Clinical Microbiology and Infectious Diseases (Copenhagen). Basel: European Society of Clinical Microbiology and Infectious Diseases, 2005.
12. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 15th informational supplement. [CLSI document M100-S15]. Vol 25. Wayne, PA: Clinical Laboratory Standards Institute, 2005.
13. National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard. 6th ed. [NCCLS document M11-A6]. Vol 24. Wayne, PA: National Committee for Clinical Laboratory Standards, 2004.
14. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 6th ed. [NCCLS document M7-A6]. Vol 23. Wayne, PA: National Committee for Clinical Laboratory Standards, 2003.
15. Kuck NA, Jacobus NV, Spengler MD, Testa RT. In vitro activity of piperacillin-tazobactam against isolates from patients enrolled in clinical trials. Int J Antimicrob Agents 1996; 7:15-21.
16. Swartz MN. Cellulitis and subcutaneous tissue infections. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious disease. 5th ed. Vol 1. Philadelphia: Churchill Livingstone, 2000:1037-57.
17. Levison ME, Bush LM. Peritonitis and other intra-abdominal infections. In: Mandell GL, Bennett JE Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious disease. 5th ed. Vol 1. Philadelphia: Churchill Livingstone, 2000:821-56.
18. Ruzin A, Visalli MA, Keeney D, Bradford PA. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 2005; 49:1017-22.
19. Visalli MA, Murphy E, Projan SJ, Bradford PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003; 47:665-9.
20. Ruzin A, Keeney D, Bradford PA. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother 2005; 49:791-3.
21. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosaPAO1. Antimicrob Agents Chemother 2003; 47:972-8.
22. Edlund C, Nord CE. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 2000; 6:159-63.
23. Goldstein EJC, Citron DM, Merriam CV, Warren Y, Tyrrell K. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother 2000; 44:2747-51.
24. Jacobus NV, McDermott LA, Ruthazer R, Snydman DR. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother 2004;48:1034-6.
25. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36:19-36.
26. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47:400-4.
27. Fritsche TR, Kriby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004; 49:201-9.
28. Zhang Y, Zhou L, Zhu D, et al. In vitro activities of tigecycline against clinical isolates from Shanghai, China. Diagn Microbiol Infect Dis 2004; 50:267-81.